BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology. Its focus within Specialty Pharmaceuticals is on antidote products that are used within hospitals. Its interventional medicine products are embolisation and drug-eluting beads used primarily to treat patients with liver tumours. Licensing & Biotechnology business area consists of licensed products and programmes and generates royalties for BTG. Effective July 8, 2013, BTG PLC acquired EKOS Corp. On July 13, 2013, the Company announced that it has completed the acquisition of Targeted Therapies division from Nordion Inc. In September 2013, the Company announced the sale of its brachytherapy business to Eckert & Ziegler Group.